Keyphrases
Clinical Outcomes
100%
Clinical Characteristics
100%
Clinical Microbiology
100%
Acute Care
100%
Houston
100%
Texas USA
100%
Ceftolozane-tazobactam
100%
Inpatient Facility
100%
Clinical Efficacy
40%
Disease Severity
10%
Clinical Data
10%
Logistic Regression Analysis
10%
Ventilator-associated Pneumonia
10%
In-hospital Mortality
10%
Hospital Discharge
10%
Demographic Data
10%
Pseudomonas Aeruginosa (P. aeruginosa)
10%
Gram-negative Bacteria
10%
Tertiary Hospital
10%
Active Agent
10%
Gram-negative
10%
Combination Therapy
10%
Multicenter Retrospective Study
10%
Bacterial Isolates
10%
Hospital Systems
10%
Patient Cohort
10%
Lactams
10%
Previous Experience
10%
Hospital-acquired
10%
Observational Cohort
10%
Clinical Success Rate
10%
β-lactamase Inhibitor
10%
Inhibitor Combination
10%
Alternative Agents
10%
Real-world Outcomes
10%
Microbiological Data
10%
MDR Pseudomonas Aeruginosa
10%
FtsI
10%
Immunology and Microbiology
Pseudomonas aeruginosa
100%
Genome Sequencing
100%
Microbiology
100%
Gram-Negative Bacteria
50%
Hospital Mortality
50%
Susceptibility
50%
Medicine and Dentistry
Emergency Care
100%
Tazobactam
100%
Ceftolozane
100%
Pseudomonas aeruginosa
20%
Genome Sequencing
20%
Primary Outcome
20%
Combination Therapy
10%
Logistic Regression Analysis
10%
Hospital Mortality
10%
Retrospective Study
10%
Penicillinase
10%
Gram-Negative Bacteria
10%
Lactam
10%
Bacterial Pneumonia
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Tazobactam
100%
Ceftolozane
100%
Pseudomonas aeruginosa
20%
Combination Therapy
10%
Penicillinase
10%
Gram Negative Bacterium
10%
Hospital Mortality
10%
Retrospective Study
10%
Lactam
10%
Bacterial Pneumonia
10%
Diseases
10%